What changed for Type 2 Diabetes
A plain English summary of what recently moved in the public data Voxsanity tracks for Type 2 Diabetes. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting worldwide 383 to 399 (+16)
- Trials on record 5,468 to 5,678 (+210)
Newly subsidised on the PBS
No medicines were newly subsidised on the PBS for Type 2 Diabetes in July 2026. Voxsanity tracks 20 PBS-subsidised medicines for this condition; none of them was listed for the first time this month.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 234 trials tracked for Type 2 Diabetes that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT06340854 · results posted 2 July 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 206 people in each of two groups — one group received a weekly insulin called insulin icodec, and the other received a daily insulin called insulin glargine. The trial ran for 26 weeks and was primarily measuring changes in a blood sugar marker called HbA1c (glycated haemoglobin), which reflects average blood sugar levels over roughly two to three months. Secondary measurements included how much time participants spent with their blood sugar in a healthy target range, their satisfaction with their diabetes treatment,...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT07465926 · results posted 22 June 2026
According to the results reported on ClinicalTrials.gov, this trial involved a very large number of people — over 278,000 in one group (those whose base diabetes medicine was a GLP-1 RA, a type of injectable or oral diabetes drug) and nearly 173,000 in another group (those whose base medicine was an SGLT2 inhibitor, another type of diabetes tablet). All participants were adults living with obesity, type 2 diabetes, and a combination of heart, kidney, and metabolic health conditions. The trial was an observational study that looked back at real-world health records to compare what happened to p...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05046886 · results posted 18 June 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 161 people across three groups: 59 in a "Usual Care Control" group (who received standard care), 61 in a "Standardised" group, and 41 in a "Personalised" group. The trial was measuring how much a person's blood sugar levels fluctuated up and down over time, using a small sensor worn on the upper arm that recorded readings every 15 minutes for up to two weeks. It also measured HbA1c — a blood test that reflects average blood sugar levels over the previous few months. Most participants finished the study: 52, 56, and 38...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04226027 · results posted 13 May 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04226027) enrolled 300 people with type 2 diabetes — 148 in a group using something called "T2.Coach" and 152 in a control group (a comparison group that did not use T2.Coach). By the end of the study, 130 people in the T2.Coach group and 136 in the control group had completed it. The trial was primarily measuring a blood marker called HbA1c — a percentage that reflects average blood sugar levels over roughly three months — at 12 months, and also tracked three secondary measures: self-care habits, confidence in managing di...
-
NCT05971940 · results posted 22 April 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT05971940) enrolled 559 adults across four groups to study the drug orforglipron at three different doses (3 mg, 12 mg, and 36 mg daily) compared to a placebo (an inactive dummy treatment). The trial's main focus was measuring changes in a blood sugar marker called HbA1c — a measure of average blood sugar levels over roughly three months — in people with type 2 diabetes. The vast majority of participants who started the trial completed it: 131 of 138 in the placebo group, 134 of 143 in the 3 mg group, 125 of 137 in the 12 m...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05238142 · results posted 16 April 2026
According to the results reported on ClinicalTrials.gov, this trial involved people with diabetes who used a continuous glucose monitoring (CGM) system — a wearable device that tracks blood sugar levels throughout the day. The trial was run in two phases. In Phase 1, 95 people started the main study period, with 89 completing it, and 66 going on to a continuation period. In Phase 2, 66 participants from Phase 1 continued alongside 236 newly enrolled participants. The trial measured two main things: "Time in Range" (TIR) — meaning the proportion of time a person's blood sugar stayed within a ta...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT06206525 · results posted 15 April 2026
According to the results reported on ClinicalTrials.gov, this trial involved 178 people in hospital who had their blood sugar levels monitored and managed with insulin. There were two groups: 38 people whose initial insulin dose was guided by a dosing calculator tool, and 140 people in an observational group whose care was managed without the calculator. The trial was measuring things like dangerously low blood sugar (below 54 mg/dL), dangerously high blood sugar (300 mg/dL or above), and average blood sugar levels in the first 24 hours after admission. The reported data shows that, for the p...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05727579 · results posted 15 April 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 41 people in total, spread across eight groups who each received the four different treatment combinations in a different order. The study was looking at whether the amount of salt a person eats changes how a diabetes medication called ertugliflozin affects blood pressure over a 24-hour period. Participants were overweight or obese adults with type 2 diabetes, and they were tested under two diet conditions — a moderate-salt diet (in line with World Health Organization recommendations) and a high-salt diet — while taki...
-
NCT04725890 · results posted 22 January 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04725890) enrolled 65 people with type 2 diabetes who received a procedure called Pulsed Electric Field (PEF) treatment using a device called Endogenex. Participants were split into two groups: those not using insulin and those already on insulin. The trial was primarily looking at whether the procedure caused any serious unexpected harms related to the device or the procedure itself within 12 weeks. It also tracked blood sugar control (using a measure called HbA1c — a percentage that reflects average blood sugar over roug...
-
NCT05394844 · results posted 1 December 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 120 people with diabetes — 61 in a group that used a continuous glucose monitor (CGM, a small wearable device that tracks blood sugar levels throughout the day) alongside diabetes education, and 59 in a group that received diabetes education alone. By the end of the study, 45 people in the CGM-plus-education group and 40 in the education-only group completed the trial. The trial was measuring several things, including blood sugar control, average glucose levels, body weight, blood pressure, and physical activity. The...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04953442 · results posted 15 September 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04953442) involved 43 participants in total — 21 in a "wait list control" group (who waited before receiving anything) and 22 in an "intervention" group (who received the program being studied). The trial appeared to be a feasibility study, meaning its main goal was not to test whether a treatment worked, but rather to check whether the study itself could be run successfully — for example, whether enough people could be recruited, whether the technology involved caused problems, and whether participants were satisfied with...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03133156 · results posted 14 August 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 93 participants across four groups: people who were healthy and lean doing moderate-intensity exercise (35 people), people who were healthy but overweight or obese doing moderate-intensity exercise (35 people), people who were overweight or obese and had type 2 diabetes doing moderate-intensity exercise (11 people), and people who were healthy and lean doing high-intensity exercise (12 people). The trial was measuring how body fat and body weight changed in these different groups after a period of exercise training. N...
-
NCT04880850 · results posted 2 July 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04880850) enrolled 582 people in total — 291 in a group receiving a once-weekly insulin called insulin icodec, and 291 in a group receiving a once-daily insulin called insulin glargine. The main thing the trial was measuring was a blood test called HbA1c (glycated haemoglobin), which gives an average picture of blood sugar levels over roughly three months. Researchers tracked this and several other blood sugar-related measures over 26 weeks (about six months). Most participants completed the trial — 275 in the icodec group...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05785832 · results posted 3 June 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 319 people with diabetes across two groups: 215 in the "Control-IQ+ AID" group (which used an automated insulin delivery system) and 104 in the "CGM Arm" (which used a continuous glucose monitor without the automated delivery component). The trial was primarily measuring changes in HbA1c — a blood test that reflects average blood sugar levels over roughly three months, expressed as a percentage. Of those who started, 211 and 102 participants respectively completed the study. The reported data shows that, for the prim...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03895996 · results posted 5 March 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03895996) enrolled 25 people in total — 16 received the investigational treatment AVT001, and 9 received a matched placebo (an inactive dummy treatment). All participants went through a procedure called leukapheresis (where blood cells are collected) and received their assigned doses. The trial was primarily measuring safety and tolerability — that is, tracking any unwanted medical events that occurred during or shortly after treatment, as well as monitoring certain blood markers. The reported data shows that, when it cam...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02010242 · results posted 28 February 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT02010242) enrolled 136 adults in total — 68 received an investigational medicine called GKT137831 and 68 received a placebo (a dummy treatment with no active ingredient). The trial was primarily looking at a measure called UACR (urine albumin-to-creatinine ratio), which reflects how much of a protein called albumin is leaking into the urine — a marker used to monitor kidney health in people with diabetes. The treatment period ran for 12 weeks, with kidney-related measurements taken at weeks 8, 10, and 12. The reported dat...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT06473662 · results posted 6 February 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT06473662) enrolled 153 participants across three groups, each receiving a different dose of the study treatment: 51 people in the 75 IU group, 50 in the 150 IU group, and 52 in the 300 IU group. The trial was measuring changes in blood sugar control and blood fats compared to where each participant started (their "baseline"). Not everyone completed the study — 33, 29, and 38 participants finished in each group respectively, meaning a notable number did not complete the trial in all three groups. The reported data shows th...
-
NCT04251156 · results posted 29 November 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04251156) enrolled 375 adults in total — 249 received semaglutide 2.4 mg (a weekly injection) and 126 received a placebo (an inactive injection). The trial ran for up to 51 weeks and was primarily measuring changes in body weight over 44 weeks. The reported data shows that, on average, participants in the semaglutide group had a body weight change of −12.5% (roughly −11.9 kg) from their starting weight by week 44, compared with −3.6% (roughly −3.4 kg) in the placebo group. When looking at how many individuals reached cert...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02637622 · results posted 29 November 2024
According to the results reported on ClinicalTrials.gov, this trial involved 1,103 participants in total — 551 in one group and 552 in another. All participants completed the study with no drop-outs recorded. Rather than testing a medicine directly, this was a survey-based study designed to understand what features of a medication matter most to patients when making choices. The two groups were asked to evaluate medication attributes using two different survey methods: one called "Best-Worst Scaling" and another called a "Discrete Choice Experiment." Both methods are ways of asking people to c...
-
NCT03717194 · results posted 20 November 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03717194) enrolled 102 people in total — 51 in an intervention group who received a medication called ertugliflozin, and 51 in a control group. By the end of the 24-week study, 48 people in the intervention group and 46 in the control group had completed the trial. The trial was measuring several aspects of how the heart was functioning, using ultrasound-based assessments of the heart muscle and its pumping activity. The reported data shows the following figures after 24 weeks. For the primary measure — a heart muscle mov...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05831644 · results posted 12 November 2024
According to the results reported on ClinicalTrials.gov, this trial involved 11 participants in total. It used a "crossover" design, meaning each person tried both the experimental treatment (called C21) and a placebo (an inactive treatment) at different times, with a washout period in between to clear each treatment from the body before switching. The trial was measuring how C21 affected blood vessel function compared to the placebo. Six participants started with C21 first, then switched to placebo, while five started with placebo first, then switched to C21. All 11 participants completed eve...
-
NCT05486065 · results posted 5 November 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT05486065) enrolled 245 participants in total, spread across four groups: three groups received different doses of an injectable medicine called semaglutide (2.0 mg, 8.0 mg, or 16.0 mg), and one group received a placebo (an inactive treatment). The trial ran for 40 weeks and was primarily measuring changes in a blood sugar marker called HbA1c — a percentage figure that reflects average blood sugar levels over roughly three months. Changes in body weight and certain medical events were also tracked as secondary measures. Th...
-
NCT05478252 · results posted 9 October 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 388 participants in total — 291 in a group labelled "Semaglutide J" and 97 in a group labelled "Semaglutide B." Both groups were taking a medicine called semaglutide, and the trial appears to have been comparing two versions of it over 28 weeks (about seven months). The trial was primarily measuring changes in a blood sugar marker called HbA1c — a percentage figure that reflects average blood sugar levels over the previous few months — and also tracked body weight and several other measures. The reported data shows t...
-
NCT04889157 · results posted 1 October 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 20 participants in total — 5 received a placebo (an inactive substance) and 15 received the investigational medicine, PF-06882961, taken twice daily. All 20 participants completed both the treatment period and the follow-up period, with no one dropping out. The trial was primarily measuring how the drug moves through the body — specifically, how much of it is absorbed into the bloodstream over time and what peak level it reaches in the blood. The reported data shows that for the main (primary) outcome measures, a sin...
-
NCT05404711 · results posted 25 September 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 40 young participants to explore whether a continuous glucose monitor (CGM) — a small sensor worn on the body that tracks blood sugar levels throughout the day — could be used at home to screen for type 2 diabetes risk. The trial was testing whether this approach was practical and acceptable to participants, and how well a home-based CGM sugar-drink test compared to the standard clinic-based blood sugar test (called an oral glucose tolerance test, or OGTT). The reported data shows that for the main question — whether...
-
NCT04265261 · results posted 25 September 2024
According to the results reported on ClinicalTrials.gov, this trial looked at a medicine called vicasinabin in two different daily doses (30 mg and 200 mg) compared to a placebo (a dummy treatment with no active ingredient) in people with diabetic retinopathy — an eye condition linked to diabetes that can threaten vision. A total of 139 people started the trial across the three groups (47 on placebo, 48 on the lower dose, and 44 on the higher dose), and the trial ran for 36 weeks. The main things being measured were whether participants' retinopathy showed meaningful improvement on a standard...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05552859 · results posted 5 September 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 62 people in total — 31 in each group. One group received a long-acting insulin called Gla-300 (insulin glargine 300 units/mL) and the other received a long-acting insulin called IDeg-100 (insulin degludec 100 units/mL). The trial ran for 24 weeks and was primarily measuring changes in HbA1c — a blood test that reflects average blood sugar levels over roughly three months. It is worth noting that of the 62 people who started the trial, only 2 (one per group) completed it, meaning the vast majority did not finish. The...
-
NCT04285983 · results posted 23 August 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 89 people who all took a once-weekly oral medication called trelagliptin (25 mg). There was no comparison group — everyone received the same treatment. The trial was primarily measuring how many participants experienced adverse drug reactions (ADRs), which are unwanted medical events considered to be linked to the study drug. Of the 89 people who started, 83 completed the study and 6 did not. The reported data shows that out of 89 participants, 6 people experienced one or more adverse drug reactions of any kind. When...
-
NCT02925676 · results posted 26 July 2024
According to the results reported on ClinicalTrials.gov, this trial looked at a device called the Hyposafe H02, which is designed to detect episodes of low blood sugar (hypoglycaemia). Eight people took part in the study, and seven completed it — one person did not finish. The trial was measuring how well the device picked up low blood sugar episodes compared to traditional finger-prick blood glucose testing, which was used as the reference check. The reported data shows two main things were measured for naturally occurring low blood sugar episodes: "sensitivity" (meaning, out of all confirme...
-
NCT03371940 · results posted 28 May 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03371940) enrolled 140 adults across four groups: one group received talk therapy (a type called Cognitive Behavioural Therapy, or CBT), one did exercise, one did both CBT and exercise combined, and one received usual care only. All participants had both diabetes and depression. The trial was measuring three main things: changes in blood sugar control (using a test called HbA1c, which reflects average blood sugar over a few months), changes in depression symptoms, and how many participants moved out of a formal diagnosis o...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
See all 234 reported results for Type 2 Diabetes
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, the United States government is currently directing a very large amount of public research funding toward Type 2 Diabetes, and this level of investment has remained broadly steady over recent years. For patients, this signals that Type 2 Diabetes is treated as a serious and ongoing research priority by one of the world's largest public funders of medical science. A s...
See the full Type 2 Diabetes page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.